These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 26065861)
1. Pulmonary and Systemic Pharmacokinetics of Colistin Following a Single Dose of Nebulized Colistimethate in Mechanically Ventilated Neonates. Nakwan N; Lertpichaluk P; Chokephaibulkit K; Villani P; Regazzi M; Imberti R Pediatr Infect Dis J; 2015 Sep; 34(9):961-3. PubMed ID: 26065861 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179 [TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. Benítez-Cano A; de Antonio-Cuscó M; Luque S; Sorlí L; Carazo J; Ramos I; Bermejo S; Campillo N; Horcajada JP; Samsó E; Grau S J Antimicrob Chemother; 2019 Nov; 74(11):3268-3273. PubMed ID: 31495877 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278 [TBL] [Abstract][Full Text] [Related]
5. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. Bihan K; Zahr N; Becquemin MH; Lu X; Bertholon JF; Vezinet C; Arbelot C; Monsel A; Rouby JJ; Langeron O; Lu Q J Antimicrob Chemother; 2018 Jun; 73(6):1639-1646. PubMed ID: 29506194 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334 [TBL] [Abstract][Full Text] [Related]
8. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664 [TBL] [Abstract][Full Text] [Related]
9. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. Marchand S; Lamarche I; Gobin P; Couet W J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428 [TBL] [Abstract][Full Text] [Related]
11. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445 [TBL] [Abstract][Full Text] [Related]
13. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772 [TBL] [Abstract][Full Text] [Related]
14. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Lu Q; Girardi C; Zhang M; Bouhemad B; Louchahi K; Petitjean O; Wallet F; Becquemin MH; Le Naour G; Marquette CH; Rouby JJ Intensive Care Med; 2010 Jul; 36(7):1147-55. PubMed ID: 20397007 [TBL] [Abstract][Full Text] [Related]
15. Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats. Lin YW; Zhou QT; Hu Y; Onufrak NJ; Sun S; Wang J; Forrest A; Chan HK; Li J Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807905 [TBL] [Abstract][Full Text] [Related]
16. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients. Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients. Boisson M; Mimoz O; Hadzic M; Marchand S; Adier C; Couet W; Grégoire N J Antimicrob Chemother; 2018 Oct; 73(10):2830-2837. PubMed ID: 29947799 [TBL] [Abstract][Full Text] [Related]